PSORIASIS

This study tested whether a new drug called CMAB015 works as well as the approved drug secukinumab for adults with moderate to severe plaque psoriasis. 336 participants received injections of either drug over 48 weeks. The main goal was to see if at least 75% of skin symptoms imp…

This study looked at whether adding metformin, a common diabetes drug, to cyclosporine works better than cyclosporine alone for treating psoriasis. Psoriasis is a chronic skin condition that causes red, scaly patches. The study included 32 adults with moderate to severe psoriasis…

This study tested a gel called SGX302 (synthetic hypericin) combined with visible light to treat mild-to-moderate psoriasis. Fifteen adults with plaque psoriasis applied the gel to their skin and received light therapy over 18 weeks. The goal was to see if the treatment could cle…

This pilot study tested higher-than-standard doses of risankizumab in 20 adults with moderate-to-severe plaque psoriasis. The goal was to see if higher doses could better clear the skin and reduce certain immune cells (resident memory T cells) that may cause the disease to return…

This study looked at 781 adults with moderate to severe plaque psoriasis who also had metabolic syndrome (a cluster of conditions like high blood pressure and obesity). Participants either received the drug Secukinumab alone or Secukinumab plus a lifestyle intervention. The goal …

This study tested whether filtering inflammatory substances from the blood using a device called Efferon CT can help people with severe psoriasis. Sixty adults with moderate-to-severe plaque psoriasis received the treatment alongside their usual therapies. The goal was to see if …

This study tested the safety and effectiveness of tofacitinib, a drug that blocks certain immune signals, for treating skin conditions like eczema and psoriasis in people with Down syndrome. 47 adolescents and adults took part. The goal was to see if the drug could improve these …

This study looked at how safe and effective OTEZLA is for people with psoriasis (skin plaques) or psoriatic arthritis when used in normal doctor visits. Over 1,000 adults who had not gotten enough relief from creams or other skin treatments took part. Researchers tracked side eff…

This study looked at whether tildrakizumab, a medicine for moderate-to-severe psoriasis, can improve blood flow to the heart. Psoriasis is linked to higher heart disease risk, and this research tested if reducing inflammation with tildrakizumab helps heart function. 36 adults wit…

This study looked at how safe and effective the drug risankizumab (brand name Skyrizi) is for adults with moderate to severe plaque psoriasis or psoriatic arthritis. Over 2,300 participants in Korea received the drug as prescribed by their doctor for 52 weeks. Researchers tracked…

This study tested an experimental drug called BMS-986322 in 109 adults with moderate-to-severe plaque psoriasis. The goal was to see if the drug safely reduces skin symptoms like redness, thickness, and scaling. Participants received either the drug or a placebo, and researchers …

This study tested a drug called orticumab in 77 adults with moderate-to-severe psoriasis who also had heart disease risk factors like obesity and high cholesterol. The goal was to see if the drug could safely improve skin symptoms and reduce inflammation. Participants received ei…

This study tested a new drug called SAR441566 in 221 adults with moderate to severe plaque psoriasis. The goal was to see if it could reduce skin symptoms like redness, thickness, and scaling. Participants took the drug or a placebo for 12 weeks, and doctors measured how much the…

This study looked at 240 adults in Taiwan with moderate to severe plaque psoriasis, a chronic skin condition causing red, scaly patches. Researchers compared the drug risankizumab to other biologic treatments to see how long it keeps skin clear. Participants were followed for abo…

This study tested whether psoriasis patients with well-controlled disease can safely reduce their dose of IL17 or IL23 inhibitor biologics without causing flare-ups. 244 adults with stable psoriasis (clear or almost clear skin for at least 6 months) were randomly assigned to eith…

This study looked at the long-term safety and effects of the drug apremilast in children aged 6 to 17 with moderate to severe plaque psoriasis. Participants who had already completed one year of treatment could continue taking the drug for up to 208 weeks (about 4 years). Researc…

This study looked at whether people with moderate-to-severe plaque psoriasis who had clear skin after 20 weeks of guselkumab treatment could keep their skin clear by getting the medicine every 16 weeks instead of the usual schedule. About 880 adults took part. The goal was to see…

This study tested whether an artificial intelligence (AI) device could help doctors better identify skin conditions. Sixteen doctors (including general practitioners and dermatologists) reviewed 29 images of various skin issues, first giving a diagnosis on their own, then with th…

This study tested an experimental drug called ASKP1240 in 60 adults with moderate to severe plaque psoriasis. The main goal was to check the drug's safety and how the body processes it, while also looking for early signs that it might improve skin symptoms. Participants received …

This study tested whether drugs that block reverse transcriptase (an enzyme) could help treat psoriasis. The idea was that these drugs might reduce inflammation caused by extra DNA inside skin cells. Only 8 people with plaque psoriasis took part, and the main goal was to see chan…

This study tested whether the drug deucravacitinib can improve quality of life for adults with moderate-to-severe plaque psoriasis. 180 participants took either the drug or a placebo for 16 weeks. The main goal was to see if more people on the drug reported little to no impact of…

This study tested a medicated foam called ARQ-154 on 22 children aged 2 to 12 with scalp and body psoriasis. The goal was to see how much of the drug gets into the blood and if it is safe. Children applied the foam once daily for two weeks, and researchers checked for side effect…

This study tested an experimental drug called BI 655130 in 59 adults with palmoplantar pustulosis (PPP), a skin condition causing painful pustules on the palms and soles. The goal was to see if the drug safely reduces the severity of pustules and redness compared to a placebo. Pa…

This early-stage study tested an oral medication called SAR441566 in 38 adults with mild to moderate psoriasis. The goal was to check safety and see if the drug improves skin symptoms over 4 weeks compared to a placebo. Participants were randomly assigned to receive either the dr…

This study tested a portable light device called Lumiton in 18 adults with psoriasis, alopecia areata (hair loss), or polymorphous light eruption (sun allergy). The goal was to see if using the device at home could improve disease severity. Researchers measured changes through ph…

This study tested a new drug called AX-158 in 31 adults with mild to moderate plaque psoriasis. Participants took either the drug or a placebo daily for 28 days, then were monitored for another 30 days. The main goal was to check safety and side effects, with some early looks at …

This study tested a 12-week online coaching program called 'Immune Strength' to see if it could improve mental health in people with psoriatic arthritis or psoriasis. 84 adults with mild to moderate depression symptoms took part. The program provided weekly access to a wellness c…

This study tested an oral medication called deucravacitinib against a placebo in 154 adults with moderate-to-severe scalp psoriasis. The goal was to see if the drug could clear or nearly clear scalp redness, thickness, and scaling by week 16. Participants had stable plaque psoria…

This study looked at whether people with mild-to-moderate psoriasis prefer using Wynzora cream compared to Enstilar foam they had used before. Thirty adults who had stopped Enstilar for at least 30 days tried Wynzora for 4 weeks. Researchers measured preference, satisfaction, how…

This pilot study tested whether a smartphone-based cognitive behavioral therapy (CBT) program could help adults with both psoriasis and depression symptoms. Thirty participants used an 8-week coach-guided app. The study measured how many people completed the program, their satisf…

This study tested whether time-restricted feeding (eating all daily calories between 8am and 2pm, then fasting for 18 hours) could reduce inflammation in men with mild to moderate psoriasis. 27 participants (including healthy volunteers) stayed at the clinic for 5 days, following…

This study tested a moisturizing medical device (RL3020-DP0364) in 40 adults with stable mild plaque psoriasis, dry skin, and itching. Participants applied the product to their whole body (except head) for 29 days. The main goal was to see if it reduced itch intensity. This is a …

This study tested a medicated lotion (IDP-118) in 16 children aged 4 to 16 with moderate to severe plaque psoriasis. Researchers measured how much of the drug entered the blood and whether it affected the body's stress hormone system. The goal was to ensure the lotion is safe for…

This study looked at whether intermittent fasting (eating only during certain hours) can reduce disease severity and improve quality of life for people with psoriasis and psoriatic arthritis. Sixty overweight adults were randomly assigned to either follow an intermittent fasting …

This study looked at skin samples from 170 people with psoriasis, atopic dermatitis (eczema), or healthy skin to understand how a protein called Lyn is involved in inflammation. Researchers measured Lyn activity and related enzymes in both affected and unaffected skin. The goal w…

This study looked at how psoriasis, a skin condition caused by inflammation, might be linked to heart disease and other metabolic problems. Researchers followed 386 adults with psoriasis for up to 4 years, using blood tests, heart scans, and imaging to measure inflammation in blo…

This study looked at fatigue in 33 adults with psoriatic arthritis or psoriasis. Researchers used questionnaires to compare tiredness levels and see how treatments and disease severity play a role. The goal was to better understand fatigue, a common but often overlooked symptom.

This study looked at the link between psoriasis (a chronic skin condition) and gum health. Researchers examined 226 adults—some with psoriasis and some without—to see if psoriasis affects the gums and overall quality of life. Participants had an oral exam and filled out questionn…

This study looked at 100 adults with moderate-to-severe psoriasis to see how two common biologic drugs (Secukinumab and Adalimumab) affect bone density. Psoriasis is a long-term inflammatory condition that can raise the risk of weak bones. The goal was to understand if these trea…

This completed Phase 1 study tested how the psoriasis drug Hemay005 is processed in people with mild to moderate kidney impairment compared to those with normal kidneys. 26 adults took a single dose, and researchers measured drug levels in the blood to guide future dosing for pat…

This study looked at skin samples from 40 people with psoriasis to understand how certain immune cells (CD4+ T cells) and a protein called S100A7 work together in the disease. Researchers used special staining techniques to measure these substances in the skin. The goal was to le…

This study looked at whether newer psoriasis medications (IL17 and IL23 inhibitors) can also help reduce early signs of heart disease. Researchers measured artery stiffness in 66 patients with moderate-to-severe psoriasis before and after one year of treatment. The goal was to se…

This study looked at how psoriasis affects blood flow and nerve sensitivity in the skin. Researchers tested 20 people with psoriasis by delivering mild substances to the skin and measuring blood flow changes. They also tested how sensitive the skin was to touch. The goal was to b…

This study followed over 2,300 adults with moderate to severe plaque psoriasis to see how safe and effective the drug secukinumab is in real-world settings. Researchers tracked side effects and how well the drug cleared skin symptoms. The goal was to gather practical evidence to …

This study aimed to create and test a patient decision aid—a tool to help people with psoriasis or psoriatic arthritis work with their doctors to choose a new treatment. Researchers worked with 37 patients and providers to design and evaluate the aid. The goal was to improve shar…

This study tested how Hemay005 tablets affect the breakdown of another drug (midazolam) and whether they change heart rhythm or inflammation levels. It involved 20 healthy adults with psoriasis. The goal was to gather safety and interaction information, not to treat the disease.

This study looked at 52 adults with psoriasis who had been on biologic drugs for at least a year. Researchers used questionnaires to find out which medical and psychological factors, like personality type, affect how satisfied patients feel with their treatment. The goal is to he…

This study tested a new questionnaire called DermCLCI-p to see if it accurately measures the long-term life impacts of moderate-to-severe psoriasis. 154 adults starting a standard treatment (risankizumab) filled out the questionnaire over 28 weeks. The goal was to validate the to…